Clinical Scorecard: Pregnancy Omega-3 Supplement Use and Reported Information Sources: An Exploratory Cross-Sectional Study
At a Glance
Category
Detail
Condition
Omega-3 supplement use and information sources during pregnancy
Key Mechanisms
DHA is a structural component of the developing fetal brain and retina; evidence for supplementation outcomes varies by outcome, baseline omega-3 status, dietary intake, dose, and population.
Target Population
Pregnant women surveyed at a university hospital in Frankfurt, Germany, from June 2024 through January 2025.
Care Setting
Hospital-based parental information evenings and outpatient antenatal appointments; findings reflect a selective university-hospital sample.
Key Highlights
The exploratory study described self-reported omega-3 supplement use during pregnancy and examined associations with reported information sources, education, and parity.
The study also examined associations between reported information sources and preconception omega-3 use.
The cross-sectional survey was voluntary and anonymous; no confirmatory hypotheses were tested.
Supplement dose, DHA/EPA content, formulation, frequency, duration, and adherence were not collected, so reported use cannot be interpreted as guideline-concordant supplementation.
The supplied article text does not report study results or the observed associations.
Guideline-Based Recommendations
Diagnosis
Management
The German Nutrition Society advises regular fatty-fish consumption and supplements containing at least 200 mg DHA daily when dietary intake is inadequate.
The WHO emphasizes adequate maternal nutrition and a balanced diet throughout pregnancy and does not recommend routine omega-3 supplementation for every pregnant woman.
Monitoring & Follow-up
Risks
Evidence for omega-3 supplementation varies by outcome and study; the source describes the strongest evidence as reduced preterm-birth risk, particularly among women with lower baseline intake or status.
Findings for cognitive development, visual function, postpartum depression, and preeclampsia are less consistent.
Patient & Prescribing Data
Pregnant women recruited at University Hospital Frankfurt through information evenings or outpatient antenatal appointments; participation was voluntary and anonymous.
Supplement use was self-reported as yes or no. The survey did not collect dose, DHA/EPA content, product formulation, frequency, duration, or adherence.
Clinical Best Practices
Interpret the survey measure as self-reported omega-3 use, not as evidence that supplementation met a guideline or dose target.
Consider that organizations differ in omega-3 intake targets and implementation approaches; the source does not describe a uniform international recommendation.
The article identifies healthcare professionals, family and social networks, printed materials, and digital resources as reported avenues for pregnancy nutrition information.
by Anna Elisabeth Hentrich, Doerthe Brueggmann, Samira Catharina Hoock, Lukas Jennewein, Nina-Naomi Kreis, Wiebke Schaarschmidt, Anne Kristina Kaempf, Frank Louwen, Eileen Deuster
